HOME ABOUT CONTACT AVAILABLE ISSUES SUBSCRIBE MEDIA & ADS
LATEST UPDATES » Special Issue 1, March 2020 – Coronavirus Outbreak       » Vol 24, No. 02, February 2020 – Fulfilling Unmet Clinical Need — Artificial Intelligence for Cancer Diagnostics       » China Completes Construction of Hospital in Record Time to Combat Wuhan Virus       » Insights to DNA Sequence of African Swine Fever Virus       » Phase III clinical trial reveals positive results for cancer immunotherapy in treating the most common form of liver cancer       » Singapore-based MedTech Start-up raises US$ 4 million in funding      
BIOBOARD - ASIA-PACIFIC
New bid to stamp out bowel cancer
Flinders researchers awarded A$553,196 for blood test to detect bowel cancer

Flinders cancer experts have been awarded a grant of A$553,196 to improve the survival and recovery of colorectal cancer patients via a simple blood test.

Bowel cancer is one of the most common cancers in Australia. Each day, 46 people are diagnosed with bowel cancer in Australia while approximately 11 people die from the disease.

Cancer Australia says less than 50 per cent of cases of bowel cancer are diagnosed at an early stage when it can be most successfully treated. In Australia, 24 percent of bowel cancers were diagnosed at stage three and 18 percent at stage four.

Chief investigator Dr Erin Symonds, principal medical scientist and team leader of the Bowel Health Service at Flinders Medical Centre said, “Despite surgery, approximately one-quarter to one-third of patients will have the cancer return within three years”.

Together with her team, they have developed and evaluated a blood test that can detect bowel cancer and if it can also be used to determine which patients are at higher risk for cancer recurrence.

If detected early, up to 90 percent of bowel cancer cases can be successfully treated.

"The blood test will hopefully be used to determine how best to treat a patient after their bowel cancer is surgically removed.

“This would allow specialists to focus therapies, especially chemotherapy, on those who are likely to most benefit - and avoid it in those who do not need it," she said.

The Cancer Australia research project, entitled ‘Personalising treatment and surveillance for colorectal cancer: prognostication with the circulating tumour-derived methylated DNA markers BCAT1 and IKZF1,’ builds on research in the field at Flinders.

The research will use the pioneering 'Colvera' blood test in patients who have already had bowel cancer - whatever their age.

A recent analysis by the Australian Institute of Health and Welfare shows that bowel cancer screening is effective in reducing bowel cancer death rates, yet participation remains low at 41 per cent.

The Australian Government is aiming to send a kit every two years to people aged 50-74 by 2020.

Click here for the complete issue.

NEWS CRUNCH  
news Joining Forces to Elevate Asia's Healthcare Industry
news 4th Global Feed Summit draws Feed Producers, Technology Providers, Raw Materials Suppliers to Bangkok for Key Discussions
news 2nd China Pharma Digital Innovation Summit to be held in Shanghai
news 2nd China Healthcare Digital Innovation Summit to be held in Shanghai
SPOTLIGHT  

MAGAZINE TAGS
About Us
Events
Available issues
Editorial Board
Letters to Editor
Contribute to APBN
Advertise with Us
CONTACT
World Scientific Publishing Co. Pte. Ltd.
5 Toh Tuck Link, Singapore 596224
Tel: 65-6466-5775
Fax: 65-6467-7667
» For Editorial Enquiries:
   biotech_edit@wspc.com or Ms Deborah Seah
» For Subscriptions, Advertisements &
   Media Partnerships Enquiries:
   biotech_ad@wspc.com
Copyright© 2020 World Scientific Publishing Co Pte Ltd  •  Privacy Policy